Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen counts on Kairos Expertise in Biobank- Management

Published: Friday, March 30, 2012
Last Updated: Friday, March 30, 2012
Bookmark and Share
Both companies plan long term partnership in which Protagen will profit from the administration and documentation of thousands of patient samples. Protagen will actively present and demonstrate the expertise of Kairos to the market.

"Protagen has established an industrial standard for automated highthroughput expression of recombinant human proteins and their respective use for biomarker development and clinical validation. In addition, we have built an excellent and unique network of internationally renowned clinical partners in all relevant indication areas”, explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen. „The expertise of Kairos will complement our technology position. In addition, it will support our collaborations with drug development companies in a very efficient way and will allow for more effective project and study management.”

Martin Zünkeler, founder and General Manager of Kairos adds "Decisive for the partnership with Protagen was the high grade of automation established in the labs, and the overall high quality of the processes employed. For instance, the fully automated aliquotation with latest robotic systems is already daily routine at Protagen. By and large, this is an ideal situation to adapt and develop software solutions for study management and biobanking”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Using Biomarkers to Identify Inflammation in Prostate Cancer Patients
Discovery of new biomarkers for chronic inflammation could allow the development of new, more accurate prostate cancer diagnostics.
Wednesday, March 30, 2016
Novel Route to Serum Based Prostate Cancer Diagnostics
Protagen AG has announced the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.
Thursday, February 11, 2016
Protagen AG Joins RA-MAP Consortium
Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has announced that it will join the RA-MAP Consortium.
Thursday, January 21, 2016
Protagen, Mikrogen Collaborate
Protagen and Mikrogen have agreed on a co-development program for a new diagnostic assay to distinguish between previously infected, seropositive individuals, from newly infected patients with active Lyme disease.
Friday, November 13, 2015
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development
The cooperation is aimed to identify and validate biomarkers for medically relevant diseases.
Monday, October 25, 2010
Key Patent of Protagen Granted in Japan
The patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology.
Friday, August 13, 2010
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!